I agree that this site is using cookies. You can find further informations here.
X
Kipps, T. J.
141  results:
Search for persons X
?
1

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cel..:

Lee, H. ; Choi, M. ; Siddiqi, T....
Hematological Oncology.  41 (2023)  S2 - p. 587-589 , 2023
Link: https://doi.org/10.1002/..
 
?
2

MURANO: Final 7 year follow up and retreatment analysis in ..:

Kater, A. P. ; Harrup, R. ; Kipps, T. J....
Hematological Oncology.  41 (2023)  S2 - p. 239-242 , 2023
Link: https://doi.org/10.1002/..
 
?
3

P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-..:

Moreno, C. ; Wierda, W. G. ; Barr, P. M....
HemaSphere.  6 (2022)  - p. 567-568 , 2022
Link: https://doi.org/10.1097/..
 
?
4

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRON..:

Coutre, S. E. ; Barr, P. M. ; Owen, C....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
5

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITU..:

Wu, J. Q. ; Seymour, J. F. ; Eichhorst, B....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIX..:

Tam, C. S. L ; Allan, J. N ; Siddiqi, T...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AN..:

Fischer, K. ; Porro Lurà, M. ; Al‐Sawaf, O....
Hematological Oncology.  37 (2019)  S2 - p. 82-84 , 2019
Link: https://doi.org/10.1002/..
 
?
8

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/..:

Wu, J. ; Bolen, C. ; Seymour, J.F....
Hematological Oncology.  37 (2019)  S2 - p. 106-108 , 2019
Link: https://doi.org/10.1002/..
 
?
9

PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATI..:

Rogers, K.A. ; Thompson, P.A. ; Allan, J.N....
Hematological Oncology.  37 (2019)  S2 - p. 60-61 , 2019
Link: https://doi.org/10.1002/..
 
?
10

FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT O..:

Tedeschi, A. ; Burger, J. ; Barr, P.M....
Hematological Oncology.  37 (2019)  S2 - p. 103-104 , 2019
Link: https://doi.org/10.1002/..
 
?
11

Leukemia-cell proliferation and disease progression in pati..:

Murphy, E J ; Neuberg, D S ; Rassenti, L Z...
Leukemia.  31 (2017)  6 - p. 1348-1354 , 2017
Link: https://doi.org/10.1038/..
 
?
12

Extended follow-up and impact of high-risk prognostic facto..:

Brown, J R ; Hillmen, P ; O'Brien, S...
Leukemia.  32 (2017)  1 - p. 83-91 , 2017
Link: https://doi.org/10.1038/..
 
?
13

LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTI..:

Montillo, M. ; Byrd, J.C. ; Hillmen, P....
Hematological Oncology.  35 (2017)  S2 - p. 235-236 , 2017
Link: https://doi.org/10.1002/..
 
?
14

INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS..:

Kipps, T.J. ; Fraser, G. ; Coutre, S.E....
Hematological Oncology.  35 (2017)  S2 - p. 109-111 , 2017
Link: https://doi.org/10.1002/..
 
?
15

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced c..:

Yu, J ; Chen, L ; Chen, Y...
Leukemia.  31 (2017)  12 - p. 2608-2614 , 2017
Link: https://doi.org/10.1038/..
 
1-15